Clinical Trials Logo

Clinical Trial Summary

Assessment of patients response and expression levels of CITED2 and HIF2a genes on adding pioglitazone to imatinib therapy.


Clinical Trial Description

Eligible denovo CML patients will be treated by combination drug therapy of imatinib 400 mg plus pioglitazone (15 - 30mg).They will be on follow up for their complete blood count (CBC), chemistry profile and random blood sugar every 2 weeks. After 3, 6 and 12 months of treatment the patients response will be evaluated and compared with the obtained responses of a historical control group. Assessment of the hypoxia induced factor 2 alpha (HIF2a) gene and CBP/p300-interacting transactivator with glutamic acid (E) and aspartic acid (D)-rich tail 2 (CITED2) gene expression levels before and after 6 months of treatment will be additionally evaluated. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04883125
Study type Interventional
Source Mansoura University
Contact
Status Completed
Phase Phase 2
Start date January 1, 2018
Completion date April 15, 2021

See also
  Status Clinical Trial Phase
Not yet recruiting NCT06409936 - PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML Phase 2
Recruiting NCT05353205 - A Study of the Efficacy and Safety of Flumatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase. Phase 4
Not yet recruiting NCT06121765 - Metabolic Alternation and Clinicohematological Characteristic in Chronic Phase CML in Patient Treated With TKI
Not yet recruiting NCT06423911 - A Phase 3 Registrational Study of Olverembatinib (HQP1351) in Patients With CML Phase 3
Recruiting NCT03459534 - A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs Phase 3
Completed NCT03885830 - Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients
Recruiting NCT02949570 - Study to Assess Efficacy and Safety of Inecalcitol in Imatinib-Treated Residual Chronic Myeloid Leukaemia: INIM Study Phase 2
Not yet recruiting NCT05367765 - A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase Phase 4
Recruiting NCT05367700 - A Study of HS-10382 in Patients With Chronic Myeloid Leukemia. Phase 1